Können 12- statt 4‑wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?

Dirk Rades

doi:10.1007/s00066-017-1191-0

Können 12- statt 4‑wöchentliche Zoledronsäuregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?

Translated title of the contribution: Can 12- instead of 4‑weekly zoledronic acid administration reduce skeletal events in patients with bone metastases?

Dirk Rades

Clinic of Radiotherapy

Translated title of the contribution	Can 12- instead of 4‑weekly zoledronic acid administration reduce skeletal events in patients with bone metastases?
Original language	German
Journal	Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Volume	193
Issue number	10
Pages (from-to)	861-863
Number of pages	3
ISSN	0179-7158
DOIs	https://doi.org/10.1007/s00066-017-1191-0
Publication status	Published - 01.10.2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00066-017-1191-0

Cite this

@article{f124dd8d3ff8467fa3c4a5e7d1a160fc,

title = "K{\"o}nnen 12- statt 4‑w{\"o}chentliche Zoledrons{\"a}uregaben skelettale Ereignisse bei Patienten mit Knochenmetastasen reduzieren?",

author = "Dirk Rades",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2017",

month = oct,

day = "1",

doi = "10.1007/s00066-017-1191-0",

language = "Deutsch",

volume = "193",

pages = "861--863",

journal = "Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]",

issn = "0179-7158",